SCHEMBL5000123

SCHEMBL5000123

O=P(O)(O)CC(O)CNO

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 2/20 0.36
GABBR1 Q9UBS5 2/20 0.36
ANPEP P15144 3/20 0.33
GABRR1 P24046 1/20 0.33
FOLH1 Q04609 4/20 0.32
ENO1 P06733 1/20 0.32
KDM4E B2RXH2 1/20 0.30
MMP2 P08253 1/20 0.30
THRB P10828 1/20 0.30
MAPK1 P28482 1/20 0.30
HSD17B10 Q99714 1/20 0.30
NAALAD2 Q9Y3Q0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11439588 1.00 GABBR2 (0.36) GABBR2GABBR1ANPEPGABRR1FOLH1
SCHEMBL11434197 0.73 ANPEP (0.38) GABBR2GABBR1ANPEPFOLH1
SCHEMBL27494652 0.72 ANPEP (0.37) GABBR2GABBR1ANPEP
SCHEMBL8764339 0.70 FDPS (0.44) ANPEPENO1KDM4EMMP2THRB
SCHEMBL17459879 0.70
SCHEMBL20471 0.70
SCHEMBL29486054 0.69 TSHR (0.43) MAPK1
SCHEMBL31612460 0.69
SCHEMBL3420169 0.69
SCHEMBL11441750 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4182758-A BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-08 US claimed
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
US-20190309289-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2019-10-10 US disclosed
US-10370654-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2019-08-06 US disclosed
US-20180320170-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2018-11-08 US disclosed
US-9944925-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. 2018-04-17 US disclosed
US-20160186168-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2016-06-30 US disclosed
EP-3027754-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING enEvolv, Inc. (US) 2016-06-08 EP disclosed
WO-2015017866-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. (US) 2015-02-05 WO disclosed
US-20080262219-A1 NOVEL CRYSTAL OF 7-[2-[(2-AMINOTHIAZOL-4-YL)-2-HYDROXYIMINOACETAMIDE-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) AND METHOD FOR PREPARATION THEREOF IMAI EIJI 2008-10-23 US disclosed
US-20070270586-A1 NOVEL CRYSTAL OF 7-[2-[(2-AMINOTHIAZOL-4-YL)-2-HYDROXYIMINOACETAMIDE-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) AND METHOD FOR PREPARATION THEREOF IMAI EIJI 2007-11-22 US disclosed
US-20070106073-A1 Novel crystal of 7-[2-[(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof ACS DOBFAR S.P.A. (IT) 2007-05-10 US disclosed
EP-1609793-A1 NOVEL CRYSTAL OF 7- 2-(2-AMINOTHIAZOLE-4-YL)-2-HYDROXYIMINOA CETAMIDO-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) AND METHOD FOR PREPARATION THEREOF ACS DOBFAR S.p.A. (IT) 2005-12-28 EP disclosed
US-4693742-A Herbicidal hydroxyamino phosphonic acids and derivatives ROHM AND HASS COMPANY (US) 1987-09-15 US disclosed
US-4206156-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) 1980-06-03 US disclosed
US-4182758-A BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070106073-A1 Novel crystal of 7-[2-[(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof CRYAA, SNCA, UACA GABBR2 4016/4885GABBR1 4085/4885ANPEP 2937/4885
US-20080262219-A1 NOVEL CRYSTAL OF 7-[2-[(2-AMINOTHIAZOL-4-YL)-2-HYDROXYIMINOACETAMIDE-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) AND METHOD FOR PREPARATION THEREOF CRYAA, SNCA, UACA GABBR2 4016/4885GABBR1 4085/4885ANPEP 2937/4885
US-20070270586-A1 NOVEL CRYSTAL OF 7-[2-[(2-AMINOTHIAZOL-4-YL)-2-HYDROXYIMINOACETAMIDE-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) AND METHOD FOR PREPARATION THEREOF CRYAA, SNCA, UACA GABBR2 4016/4885GABBR1 4085/4885ANPEP 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.